Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AstraZeneca

1,787.50 SEK-1.97 %19/11 16:07
Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-1.97 %
+8.76 %
+16.98 %
+3.98 %
+4.93 %
+5.99 %
+32.07 %
+77.58 %
+9,680.85 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.77T SEK
Turnover
451.3M SEK
Revenue
540.24B
EBIT %
23.4 %
P/E
29.45
Dividend yield-%
1.65 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
9/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-11-19 08:01

AstraZeneca: Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers

AstraZeneca
Press release2026-11-16 08:12

AstraZeneca: Perioperative approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer

AstraZeneca
Press release2026-11-16 08:05

AstraZeneca: Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-16 08:02

AstraZeneca investerar 30 miljoner i obesitasforskning

AstraZeneca
Press release2026-11-16 08:00

AstraZeneca: Klygefa (gefurulimab) approved in the EU for the treatment of adults with generalised myasthenia gravis (gMG)

AstraZeneca
Press release2026-11-13 12:46

AstraZeneca: Baxfendy (baxdrostat) recommended for approval in the EU for the treatment of adults with hypertension

AstraZeneca
Regulatory press release2026-10-30 08:00

Resultat för AstraZeneca: Första nio månaderna samt tredje kvartalet 2026

AstraZeneca
Press release2026-10-27 08:35

AstraZeneca: Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

AstraZeneca
Regulatory press release2026-10-27 08:30

AstraZeneca: Enhertu approved in EU for HER2-positive eBC

AstraZeneca
Press release2026-10-25 16:41

AstraZeneca: Sonesitatug vedotin reduced the risk of death by 42% in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

AstraZeneca
Press release2026-10-25 16:37

AstraZeneca: Tagrisso plus Orpathys reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on Tagrisso

AstraZeneca
Press release2026-10-24 16:37

AstraZeneca: Imfinzi plus Imdelltra reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

AstraZeneca
Press release2026-10-24 16:31

AstraZeneca: Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

AstraZeneca
Press release2026-10-22 08:00

AstraZeneca: Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy

AstraZeneca
Press release2026-10-20 15:11

AstraZeneca: Tezspire positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission

AstraZeneca
Press release2026-10-20 06:06

AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes

AstraZeneca
Press release2026-10-19 08:06

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys

AstraZeneca
Press release2026-10-15 12:00

AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseases

AstraZeneca
Press release2026-10-11 23:01

AstraZeneca: Efzimfotase alfa showed numerical improvement in 6-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents, adults with HPP at week 25 in HICKORY Ph3 trial

AstraZeneca
Press release2026-10-06 08:06

AstraZeneca: Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting

AstraZeneca